For most drugs, the molecule is the asset and the factory is a cost center. For an autologous cell therapy, that logic inverts: the patient's own cells are the starting material, and the manufacturing process — how those cells are grown, restimulated, and shipped back — is much of what a company actually owns. That is the lens to read Iovance Biotherapeutics' patent activity through, and the first week of June 2026 added a fresh grant to the pile. On 2 June 2026, the U.S. patent office issued US12642816B2, titled "Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy."

Tumor-infiltrating lymphocytes (TILs) are immune cells harvested from a patient's own tumor, expanded in enormous numbers in a manufacturing facility, and infused back to attack the cancer. The bottleneck has never really been the biology of whether the cells work — it is the logistics of growing a personalized batch reliably, quickly, and without contamination. The issued patent's own summary states the problem and the claimed answer plainly:

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.— Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy, US12642816B2

The phrase that matters commercially is "closed system." A closed manufacturing process — one where the cells are not exposed to the open environment between steps — is what lets a personalized therapy scale across many patients at once without each batch becoming a contamination roulette. By issuing claims on that process, Iovance is fencing the part of the value chain that is hardest for a competitor to design around, because a rival making its own TIL product has to grow cells somehow, and the granted process space narrows the routes available.

The economics behind that fence are worth spelling out. An autologous cell therapy is manufactured one patient at a time — there is no inventory of finished product sitting in a warehouse, because the starting material is the individual patient's own cells. Every batch is a custom run, and the cost, the turnaround time, and the failure rate of that run are not back-office details; they are central to whether the therapy can be delivered at scale and at a viable price. A method that shortens the expansion timeline, reduces the number of open handling steps, and lowers contamination risk attacks all three of those variables at once. That is why the manufacturing claims are the commercially load-bearing ones for this kind of product, and why a company in the space concentrates its issued coverage there rather than on the cells in the abstract.

The same theme, issued again and again

What makes this a coverage map rather than a single data point is how many times the same idea has issued. The 2 June grant did not arrive alone. The same day, the office issued US12642268B2, "Closed process for expansion and gene editing of tumor infiltrating lymphocytes," which extends the closed-system approach to TILs that have been gene-edited to enhance their activity — a forward step that pairs the manufacturing method with editing. A week later, on 9 June, US12648962B2 issued under the same "Processes for production of tumor infiltrating lymphocytes" title, and on 16 June US12655389B2 followed with the same title again. Four issued patents in three weeks, all circling the production process, is the signature of a company building a thicket around one method rather than chasing scattered ideas.

That recent cluster sits on a foundation that goes back years. US10517894B2 covers the restimulation of cryopreserved TILs — the step that revives frozen cells before infusion, which is what makes a shippable, off-the-shelf-logistics model possible for a personalized product. And US10415015B2 covers engineered artificial antigen-presenting cells used to drive TIL expansion — the reagent side of the same manufacturing question. Restimulation, expansion, the cells that feed expansion, and the closed system that contains all of it: the issued footprint reads as a deliberately layered claim set over the full production workflow.

What the issued coverage buys, in business terms

The reason this concentration is worth a business reader's attention is that it shapes freedom-to-operate for anyone else in adoptive cell therapy. A granted claim is enforceable — it is the part of an estate a company can actually assert — and Iovance's grants are clustered on the method of making the product. Competitors pursuing their own TIL or TIL-adjacent therapies have to grow and restimulate cells through some process; the more of that process space is occupied by issued claims, the more a newcomer's manufacturing choices are constrained, and the more licensing or design-around work sits between them and the clinic. The records also show the estate is still growing rather than mature: grants issued on 2 June, 9 June, and 16 June 2026 indicate continuations and related filings are still converting into issued coverage, which extends the timeline over which the manufacturing claims stay live.

The usual caveats apply, and they are worth stating precisely. A coverage map describes what has issued, not how a court would construe or whether any claim survives a challenge — issued is not the same as unassailable. The CPC classifications on these grants cluster in C12N 5/0636 and related cell-culture classes, A61K 35/17 (the cell-therapy preparation class), and A61P 35/00 (antineoplastic use), which confirms the filings are about cell-manufacturing and cancer treatment rather than a small-molecule or antibody claim. But the throughline is hard to miss: across a single month in mid-2026 and a multi-year backlog of related grants, Iovance has been issued claim after claim over how a TIL therapy gets made. In a modality where the process is the product, that is the part of the footprint that defines the business edge — and the records show it is exactly where the company has concentrated its issued coverage.